The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 1.45
High: 1.45
Low: 1.40
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Imaging Biometrics and QMENTA announce partnership

13 Jun 2018 07:00

RNS Number : 1663R
Flying Brands Limited
13 June 2018
 

Flying Brands PLC

("Flying Brands" or the "Company")

Imaging Biometrics and QMENTA announce a partnership to increase accuracy in research.

 

Imaging Biometrics®, LLC ("IB"), a subsidiary of Flying Brands Limited (LON:FBDU), announces today that it has entered into a partnership to accelerate neuroscience research and increase accuracy in diagnostics support. Imaging Biometrics will integrate all IB modules; IB Neuro, IB Delta T1 Maps, IB Diffusion, and IB DCE onto the cloud-based QMENTA platform that provides advanced data analysis and management for neuro experts.

 

The integration of IB's software is the first FDA cleared option on the QMENTA platform to be uploaded via its Software Development Kit ("SDK"). The SDK has been developed by QMENTA's engineers to enable third party companies or researchers with algorithms to integrate them on the platform to easily share them with the neuroscience community. This goes along with QMENTA's aim to bolster collaboration, whether it be between researchers, neurologists, developers, or even with other companies.

 

Quote from Imaging Biometrics' CEO, Michael Schmainda

"Our partnership with QMENTA enables efficient and immediate access to our quantitative imaging solutions to those involved in clinical trials and research. It is exciting to be part of QMENTA's neuro-centric platform and helping advance the understanding of neurological disorders."

 

Quote from QMENTA's CEO, Paulo Rodrigues, PhD

"We are very proud of this new partnership as it is the first FDA cleared tool we will be implementing on our SDK. We believe this partnership will improve our customers' satisfaction, because they know they can trust and rely on powerful and efficient tools such as the ones that Imaging Biometrics is developing." 

About the partners

Imaging Biometrics, a subsidiary of Flying Brands Limited (LON:FBDU), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

QMENTA offers a cloud-based platform to streamline the medical imaging workflow for running clinical trials. QMENTA's aim is to accelerate the discovery and development of new treatments for neurological diseases using state-of-the-art image processing techniques. QMENTA has been growing since 2013 in EU & US, now supporting many multi-center studies and a number of clinical trials. The company was named "Best New Radiology Vendor" in 2017 by Aunt Minnie and was a European Winner for Accenture's Healthtech Innovation Challenge. More recently, QMENTA has been invited by Sanofi to attend VivaTech in Paris and won one of the Sanofi Tech Lab challenges for its innovative technology. For more information on the company, visit www.qmenta.com.

 

Flying Brands Limited (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For further information, please contact:

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

-Ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRGMGMVKZLGRZM
Date   Source Headline
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial
2nd Sep 20217:00 amRNSBoard Changes
1st Sep 202110:00 amRNSStart of Trading on the OTCQB Venture Market
27th Aug 20219:57 amRNSHalf Yearly Report
11th Jun 20214:41 pmRNSSecond Price Monitoring Extn
11th Jun 20214:36 pmRNSPrice Monitoring Extension
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20218:00 amRNSIQAI Awarded “Gad-Free” Patent
4th Jun 20217:00 amRNSIB Software Chosen by LA County Hospital
19th May 202112:06 pmRNSResult of AGM
27th Apr 20213:27 pmRNSNotice of AGM
20th Apr 202110:21 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:27 amRNSIQAI commits to Phase 1 study
6th Apr 20217:00 amRNSFive Year NCI Award Grant to IB
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.